Meridian Bioscience Supports Diagnostic Companies in Fighting Coronavirus Pandemic by Providing Zero Cost Proprietary Technology for Evaluation
March 16, 2020 11:51 ET
|
Meridian Bioscience Inc.
CINCINNATI, March 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its increased commitment to the global fight against COVID-19 by making available zero cost...
Meridian Bioscience Announces FDA-Clearance for New Curian™ Analyzer and the Curian™ HpSA® Assay
March 16, 2020 08:00 ET
|
Meridian Bioscience Inc.
CINCINNATI, March 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of immunoassay, molecular, and blood chemistry diagnostic testing solutions, today announced that...
Meridian’s Novel Air-Dryable qPCR Mix Decreases Costs and Simplifies Workflows for Molecular Test Manufacturers
February 26, 2020 08:00 ET
|
Meridian Bioscience Inc.
CINCINNATI, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), following the extremely successful launch of the Lyo-Ready qPCR mixes, is proud to introduce today its...
Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform
February 19, 2020 09:15 ET
|
Meridian Bioscience Inc.; Exalenz Bioscience
CINCINNATI and MODIIN, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) and Exalenz Bioscience Ltd. (TASE: EXEN) announced today that the two companies have entered...
Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results and Reaffirms 2020 Guidance
February 07, 2020 07:30 ET
|
Meridian Bioscience Inc.
CINCINNATI, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2019. First Quarter Fiscal 2020...
Meridian Bioscience Lyo-Ready 1-Step RT-qPCR Mix is Used in the Development of Molecular Diagnostics for New Coronavirus Outbreak
January 27, 2020 09:17 ET
|
Meridian Bioscience Inc.
CINCINNATI, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced a novel coronavirus, identified by Chinese authorities on January 7 and currently named...
Meridian lanza nueva polimerasa de alta fidelidad para ofrecer amplificación robusta para aplicaciones NGS y PCR
January 23, 2020 16:46 ET
|
Meridian Bioscience Inc.
CINCINNATI, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) anuncia hoy el lanzamiento de Mix HS de Pfu de Alta Especificidad que además de ofrecer amplificación de alta...
메리디안, NGS와 PCR 애플리케이션에 강력한 증폭 능력을 제공하는 정확성 높은 중합효소 공개
January 23, 2020 16:46 ET
|
Meridian Bioscience Inc.
신시내티, Jan. 24, 2020 (GLOBE NEWSWIRE) -- 메리디안 바이오사이언스(Meridian Bioscience, Inc.)(NASDAQ: VIVO)는 정확성 높은 증폭 능력과 함께 동반진단(CDx) 및 임상 테스트용 증폭 능력을 제공하는 High-Specificity Pfu HS Mix를 공개했다. 정확성 높은 증폭 능력은...
Meridian 推出一種新的高保真聚合酶，可為 NGS 和 PCR 應用提供可靠的擴增
January 23, 2020 16:46 ET
|
Meridian Bioscience Inc.
辛辛那提, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) 今天宣佈推出高特異性 Pfu HS Mix，不但可提供高保真擴增，而且提供具有市場領先地位的擴增，用於伴隨診斷 (CDx) 和臨床測試。 高保真擴增對於結果取決於正確 DNA 序列的應用至關重要，例如下一代測序...
Meridian推出了一种新的高保真聚合酶，为NGS和PCR应用提供稳健的扩增
January 23, 2020 16:46 ET
|
Meridian Bioscience Inc.
辛辛那提, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience，Inc.（纳斯达克：VIVO）今天宣布推出一种高特异性的Pfu-HS组合，不仅提供高保真度扩增，还为伴诊 (CDx) 和临床试验提供市场领先的扩增。 对于结果取决于正确DNA序列的应用（例如下一代测序...